SG11201910206QA - Methods and compositions for treating inflammatory gastrointestinal disorders - Google Patents
Methods and compositions for treating inflammatory gastrointestinal disordersInfo
- Publication number
- SG11201910206QA SG11201910206QA SG11201910206QA SG11201910206QA SG 11201910206Q A SG11201910206Q A SG 11201910206QA SG 11201910206Q A SG11201910206Q A SG 11201910206QA SG 11201910206Q A SG11201910206Q A SG 11201910206QA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- suite
- eosinophilic
- road
- california
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 208000018522 Gastrointestinal disease Diseases 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 230000002757 inflammatory effect Effects 0.000 title abstract 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 4
- 206010057271 eosinophilic colitis Diseases 0.000 abstract 3
- 201000001561 eosinophilic gastritis Diseases 0.000 abstract 3
- 206010064212 Eosinophilic oesophagitis Diseases 0.000 abstract 2
- 101000863884 Homo sapiens Sialic acid-binding Ig-like lectin 8 Proteins 0.000 abstract 2
- 201000000708 eosinophilic esophagitis Diseases 0.000 abstract 2
- 201000001564 eosinophilic gastroenteritis Diseases 0.000 abstract 2
- 102000051056 human SIGLEC8 Human genes 0.000 abstract 2
- 102220240796 rs553605556 Human genes 0.000 abstract 2
- 235000003889 Paeonia suffruticosa Nutrition 0.000 abstract 1
- 240000005001 Paeonia suffruticosa Species 0.000 abstract 1
- 208000010643 digestive system disease Diseases 0.000 abstract 1
- 210000003979 eosinophil Anatomy 0.000 abstract 1
- 230000002327 eosinophilic effect Effects 0.000 abstract 1
- 208000018685 gastrointestinal system disease Diseases 0.000 abstract 1
- 210000003630 histaminocyte Anatomy 0.000 abstract 1
- 210000000936 intestine Anatomy 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
- A61K39/001113—CD22, BL-CAM, siglec-2 or sialic acid- binding Ig-related lectin 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
- A61K39/225—Porcine transmissible gastroenteritis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06V—IMAGE OR VIDEO RECOGNITION OR UNDERSTANDING
- G06V20/00—Scenes; Scene-specific elements
- G06V20/60—Type of objects
- G06V20/69—Microscopic objects, e.g. biological cells or cellular parts
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Communicable Diseases (AREA)
- General Physics & Mathematics (AREA)
- Multimedia (AREA)
- Theoretical Computer Science (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 08 November 2018 (08.11.2018) WIPO I PCT omit VIII °nolo III VIII VIII IID No oimIE (10) International Publication Number WO 2018/204871 Al (51) International Patent Classification: A61K 39/395 (2006.01) A61P 37/00 (2006.01) A61P 1/00 (2006.01) C07K 16/28 (2006.01) (21) International Application Number: PCT/US2018/031231 (22) International Filing Date: 04 May 2018 (04.05.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/502,480 05 May 2017 (05.05.2017) US 62/572,337 13 October 2017 (13.10.2017) US (71) Applicant: ALLAKOS INC. [US/US]; 75 Shoreway Road, Suite A, San Carlos, California 94070 (US). (72) Inventors: BEBBINGTON, Christopher Robert; c/o Al- lakos Inc., 75 Shoreway Road, Suite A, San Carlos, Cali- fornia 94070 (US). YOUNGBLOOD, Bradford Andrew; c/o Allakos Inc., 75 Shoreway Road, Suite A, San Car- los, California 94070 (US). TOMASEVIC, Nenad; c/o Al- lakos Inc., 75 Shoreway Road, Suite A, San Carlos, Cali- fornia 94070 (US). BROCK, Emily C.; c/o Allakos Inc., 75 Shoreway Road, Suite A, San Carlos, California 94070 (US). (74) Agent: JONES, Kevin; Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, California 94304-1018 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (54) Title: METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY GASTROINTESTINAL DISORDERS Blood Eosinophils me PBS + No OVA izotypo + ovA ssm Anti-Siglec-8 Ats + OVA N cc O 00 O C Tissue Eosinophils Tissue Mast Cells Small intasttna Bolan Intestine (57) : The present disclosure provides methods for the treatment of inflammatory bowel disease (IBD) or an eosinophilic gas- trointestinal disorder (EGID), such as eosinophilic esophagitis (EOE), eosinophilic gastritis (EG), eosinophilic gastroenteritis (EGE), and eosinophilic colitis (EC). In particular, the present disclosure provides methods for the treatment of IBD or an EGID through ad- ministration of antibodies that bind to human Siglec-8 or compositions comprising said antibodies. The present disclosure also provides articles of manufacture or kits comprising antibodies that bind to human Siglec-8 for the treatment of IBD or an EGID. [Continued on next page] WO 2018/204871 Al MIDEDIMOMOIDEIRDERI0010101111NOMHIMEMOIMIE (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to non prejudicial disclosures or exceptions to lack of novelty (Rule 4.17(v)) Published: with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a))
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762502480P | 2017-05-05 | 2017-05-05 | |
| US201762572337P | 2017-10-13 | 2017-10-13 | |
| PCT/US2018/031231 WO2018204871A1 (en) | 2017-05-05 | 2018-05-04 | Methods and compositions for treating inflammatory gastrointestinal disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201910206QA true SG11201910206QA (en) | 2019-11-28 |
Family
ID=64016746
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201910206Q SG11201910206QA (en) | 2017-05-05 | 2018-05-04 | Methods and compositions for treating inflammatory gastrointestinal disorders |
| SG10202112259VA SG10202112259VA (en) | 2017-05-05 | 2018-05-04 | Methods and compositions for treating inflammatory gastrointestinal disorders |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202112259VA SG10202112259VA (en) | 2017-05-05 | 2018-05-04 | Methods and compositions for treating inflammatory gastrointestinal disorders |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20200270344A1 (en) |
| EP (1) | EP3618872A4 (en) |
| JP (2) | JP7346304B2 (en) |
| KR (1) | KR20200015511A (en) |
| CN (1) | CN111246880A (en) |
| AU (1) | AU2018263937A1 (en) |
| BR (1) | BR112019022957A2 (en) |
| CA (1) | CA3062430A1 (en) |
| IL (1) | IL270304B1 (en) |
| MX (1) | MX2019013136A (en) |
| SG (2) | SG11201910206QA (en) |
| WO (1) | WO2018204871A1 (en) |
| ZA (1) | ZA201907372B (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10774145B2 (en) | 2015-06-17 | 2020-09-15 | Allakos Inc. | Methods and compositions for treating fibrotic diseases |
| MX2019013137A (en) | 2017-05-05 | 2020-07-14 | Allakos Inc | Methods and compositions for treating allergic ocular diseases. |
| MX2021009626A (en) * | 2019-02-15 | 2021-09-08 | Allakos Inc | Methods and compositions for treating mast cell gastritis, mast cell esophagitis, mast cell enteritis, mast cell duodenitis, and/or mast cell gastroenteritis. |
| WO2021026021A1 (en) * | 2019-08-02 | 2021-02-11 | Allakos Inc. | Methods of administering anti-siglec-8 antibodies and corticosteroids |
| WO2021081411A1 (en) * | 2019-10-24 | 2021-04-29 | Allakos Inc. | Methods and compositions for treating irritable bowel syndrome and functional dyspepsia |
| WO2023141097A1 (en) * | 2022-01-24 | 2023-07-27 | Children's Hospital Medical Center | Methods of treating eosinophilic colitis |
| CN117187180B (en) * | 2023-11-03 | 2024-01-26 | 四川大学 | Th17 cell, culture method and application thereof and induction liquid thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005116088A2 (en) * | 2004-05-25 | 2005-12-08 | The Johns Hopkins University | Methods and compositions for treating diseases and disorders associated with siglec-8 expressing cells |
| US20100267934A1 (en) * | 2007-05-31 | 2010-10-21 | Genmab A/S | Stable igg4 antibodies |
| WO2010063785A2 (en) * | 2008-12-03 | 2010-06-10 | Genmab A/S | Antibody variants having modifications in the constant region |
| EP2465873A1 (en) * | 2010-12-16 | 2012-06-20 | Deutsches Rheuma-Forschungszentrum Berlin | Eosinophils as a therapeutic target |
| CA2840522A1 (en) * | 2011-06-23 | 2012-12-27 | Children's Hospital Medical Center | Molecular diagnostic panel of eosinophilic gastrointestinal disorders |
| US9260756B2 (en) * | 2012-02-24 | 2016-02-16 | Children's Hospital Medical Center | Esophageal microRNA expression profiles in eosinophilic esophagitis |
| TWI634900B (en) * | 2013-07-11 | 2018-09-11 | 再生元醫藥公司 | Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor |
| HUE047283T2 (en) * | 2013-12-09 | 2020-04-28 | Allakos Inc | Anti-siglec-8 antibodies and methods of use thereof |
| JP6825909B2 (en) * | 2014-02-28 | 2021-02-03 | アラコス インコーポレイテッド | Methods and Compositions for Treating SIGLEC-8 Related Diseases |
| US10774145B2 (en) * | 2015-06-17 | 2020-09-15 | Allakos Inc. | Methods and compositions for treating fibrotic diseases |
| MX2019013137A (en) * | 2017-05-05 | 2020-07-14 | Allakos Inc | Methods and compositions for treating allergic ocular diseases. |
| MX2021009626A (en) * | 2019-02-15 | 2021-09-08 | Allakos Inc | Methods and compositions for treating mast cell gastritis, mast cell esophagitis, mast cell enteritis, mast cell duodenitis, and/or mast cell gastroenteritis. |
| ES2965508T3 (en) * | 2019-06-07 | 2024-04-15 | Epithelion Science Biotech S L | Irsogladine for the treatment of eosinophilic gastrointestinal diseases |
| WO2021026021A1 (en) * | 2019-08-02 | 2021-02-11 | Allakos Inc. | Methods of administering anti-siglec-8 antibodies and corticosteroids |
| WO2021081411A1 (en) * | 2019-10-24 | 2021-04-29 | Allakos Inc. | Methods and compositions for treating irritable bowel syndrome and functional dyspepsia |
-
2018
- 2018-05-04 JP JP2019560756A patent/JP7346304B2/en active Active
- 2018-05-04 CA CA3062430A patent/CA3062430A1/en active Pending
- 2018-05-04 MX MX2019013136A patent/MX2019013136A/en unknown
- 2018-05-04 SG SG11201910206Q patent/SG11201910206QA/en unknown
- 2018-05-04 BR BR112019022957A patent/BR112019022957A2/en unknown
- 2018-05-04 US US16/610,429 patent/US20200270344A1/en active Pending
- 2018-05-04 EP EP18795249.4A patent/EP3618872A4/en active Pending
- 2018-05-04 SG SG10202112259VA patent/SG10202112259VA/en unknown
- 2018-05-04 CN CN201880044727.6A patent/CN111246880A/en active Pending
- 2018-05-04 AU AU2018263937A patent/AU2018263937A1/en active Pending
- 2018-05-04 KR KR1020197035570A patent/KR20200015511A/en not_active Application Discontinuation
- 2018-05-04 WO PCT/US2018/031231 patent/WO2018204871A1/en active Application Filing
- 2018-05-04 IL IL270304A patent/IL270304B1/en unknown
-
2019
- 2019-11-06 ZA ZA2019/07372A patent/ZA201907372B/en unknown
-
2023
- 2023-05-15 JP JP2023080140A patent/JP2023099232A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018263937A1 (en) | 2019-12-05 |
| JP7346304B2 (en) | 2023-09-19 |
| WO2018204871A1 (en) | 2018-11-08 |
| IL270304B1 (en) | 2024-03-01 |
| MX2019013136A (en) | 2020-07-14 |
| US20200270344A1 (en) | 2020-08-27 |
| CA3062430A1 (en) | 2018-11-08 |
| EP3618872A1 (en) | 2020-03-11 |
| JP2023099232A (en) | 2023-07-11 |
| SG10202112259VA (en) | 2021-12-30 |
| JP2020518645A (en) | 2020-06-25 |
| CN111246880A (en) | 2020-06-05 |
| IL270304A (en) | 2019-12-31 |
| KR20200015511A (en) | 2020-02-12 |
| ZA201907372B (en) | 2024-04-24 |
| EP3618872A4 (en) | 2021-06-30 |
| BR112019022957A2 (en) | 2020-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201910206QA (en) | Methods and compositions for treating inflammatory gastrointestinal disorders | |
| SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
| SG11201907753TA (en) | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof | |
| SG11201809089QA (en) | Bispecific binding proteins and uses thereof | |
| SG11201909949XA (en) | Targeted immunotolerance | |
| SG11201805532XA (en) | Multivalent and multispecific 41bb-binding fusion proteins | |
| SG11201909160WA (en) | Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201908391XA (en) | Methods for modulating an immune response | |
| SG11201900885VA (en) | Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule | |
| SG11201805422WA (en) | Multivalent and multispecific ox40-binding fusion proteins | |
| SG11201810933QA (en) | Anti-c5 antibodies and uses thereof | |
| SG11201810927QA (en) | Pd-l1-specific antibodies and methods of using the same | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201909303TA (en) | Point of delivery cold slurry generation | |
| SG11201907889YA (en) | Glycan-interacting compounds and methods of use | |
| SG11201806496SA (en) | Antigen binding proteins that bind pd-l1 | |
| SG11201906238TA (en) | Split sector level sweep using beamforming refinement frames | |
| SG11201907583TA (en) | Methods for treating complement-mediated diseases and disorders | |
| SG11201810757YA (en) | Non-human animals expressing exogenous terminal deoxynucleotidyltransferase | |
| SG11201804673WA (en) | Novel anti-claudin antibodies and methods of use | |
| SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
| SG11201908743SA (en) | Methods and compositions for modulation of immune cells | |
| SG11201906552WA (en) | TGF-ß DECOY RECEPTOR | |
| SG11201907420VA (en) | Inhibition of smarca2 for treatment of cancer |